Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lambda/Ribavirin/Daclatasvir in HCV with Hemophilia (MAGNITUDE)
NCT01741545Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2013
- Primary completion
- Jan 2015
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of peginterferon lambda-1a, daclatasvir in hepatitis C (HCV), sponsored by Bristol Myers Squibb. Started Mar 2013; status: completed.
02
Drugs
peginterferon lambda-1adaclatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01741545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01741545.